Phathom Pharmaceuticals, Inc. Stock Price, News & Analysis

Phathom Pharmaceuticals (Nasdaq: PHAT) announces the completion of patient enrollment in its pivotal Phase 3 clinical trial, PHALCON-EE, for vonoprazan, targeting the healing and maintenance of erosive esophagitis (EE) and heartburn relief. The trial exceeded its enrollment goal of 1,000 patients, with topline results expected in the second half of 2021. This trial complements another study, PHALCON-HP, assessing vonoprazan in H. pylori eradication. Vonoprazan has demonstrated promising efficacy and safety as a potassium-competitive acid blocker, recently receiving Fast Track designation from the FDA.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced its management team will participate in two virtual investor conferences in December 2020:

• Evercore ISI 3rd Annual HealthCONx Conference
  Date: December 1, 2020
  Live Presentation Time: 10:55 am ET
• Piper Sandler 32nd Annual Virtual Healthcare Conference
  Date: December 2, 2020
  Pre-recorded presentation available online

Additionally, one-on-one meetings will be held during these events. For access to the presentations, visit Phathom's website.

Phathom Pharmaceuticals (Nasdaq: PHAT) will host a virtual Investor Day on December 14, 2020, from 1 PM to 3:30 PM ET. The event will feature members of Phathom's management team and gastroenterology experts discussing the company's pipeline and commercial strategy. Interested participants can pre-register for the event. A replay and presentation slides will be available post-event on Phathom's website.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced that its management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 3:15 p.m. GMT (10:15 a.m. ET). The conference runs from November 17-19, 2020, where the team will also engage in one-on-one meetings. Interested parties can access the live webcast and recorded presentations via the Phathom website. The company specializes in developing treatments for gastrointestinal diseases, focusing on the novel potassium competitive acid blocker, vonoprazan.

Phathom Pharmaceuticals (Nasdaq: PHAT) reported third-quarter 2020 financial results and provided updates on its pivotal Phase 3 clinical trials for vonoprazan. The company expects to complete enrollment in the PHALCON-EE trial by year-end 2020 and in the PHALCON-HP trial by Q1 2021. Top-line results are anticipated in mid-2021. The net loss for Q3 2020 was $34.1 million, down from $68.1 million in Q3 2019. Cash and equivalents stood at $226.4 million as of September 30, 2020. Phathom is enhancing its team with seasoned biopharmaceutical leaders in preparation for vonoprazan’s potential launch.

Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 3:30 p.m. ET. The management team will engage in one-on-one meetings throughout the virtual conference, which runs from September 14-18, 2020. Phathom focuses on developing novel treatments for gastrointestinal diseases, including a late-stage development drug, vonoprazan, aimed at treating acid-related disorders. Recorded sessions will be available for 60 days post-event.

Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2020 results, highlighting a net loss of $21.1 million, significantly reduced from $87.8 million in Q2 2019. This improvement was attributed to lower non-cash charges, which dropped from $57.5 million to $0.8 million. Research and development expenses surged to $14.9 million, reflecting increased clinical costs and staffing. Cash reserves stood at $247.3 million. The company resumed patient enrollment in its Phase 3 trials for vonoprazan, with topline data expected in 2021. Todd Branning was appointed CFO, enhancing the leadership team.

Phathom Pharmaceuticals (NASDAQ: PHAT) has appointed Todd Branning as Chief Financial Officer, transitioning from Interim CFO David Socks, who will remain a strategic advisor and Board member. Branning brings over 25 years of experience in finance from companies like Amneal Pharmaceuticals and Teva Pharmaceuticals, enhancing Phathom's leadership amid the potential commercialization of vonoprazan. This oral potassium-competitive acid blocker has received FDA's Fast Track status for treating H. pylori infection, supporting its promising market position.

Phathom Pharmaceuticals (Nasdaq: PHAT) has restarted patient enrollment in its Phase 3 clinical trials, PHALCON-EE and PHALCON-HP, following a temporary pause due to the COVID-19 pandemic. The trials focus on evaluating the efficacy of vonoprazan, a new treatment for gastrointestinal diseases. Phathom expects to provide top-line data in 2021. The FDA has designated vonoprazan as a qualified infectious disease product, enhancing its development prospects. The trials will assess safety and effectiveness for conditions like erosive esophagitis and H. pylori infection.